Study: GSK cervical cancer vaccine promising for older women

06/5/2006 | MSNBC

GlaxoSmithKline reports its cervical cancer vaccine Cervarix, a likely competitor to Merck's Gardasil, produced immune responses in all women ages 15 to 55 in a clinical study. The company said the study was the first evidence such a vaccine may be effective in women ages 26 and older and also reported the vaccine was "generally safe and well-tolerated."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA